key: cord-0968814-jyyuq9dp
authors: McLaughlin, Katie-May; Bojkova, Denisa; Bechtel, Marco; Kandler, Joshua D.; Reus, Philipp; Le, Trang; Wagner, Julian U. G.; Ciesek, Sandra; Wass, Mark N.; Michaelis, Martin; Cinatl, Jindrich
title: CD47 as a potential biomarker for the early diagnosis of severe COVID-19
date: 2021-03-01
journal: bioRxiv
DOI: 10.1101/2021.03.01.433404
sha: 5ea7236d2332c90457756a0f06b63fcc5ef88940
doc_id: 968814
cord_uid: jyyuq9dp

The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune response resulting in hyperinflammation. Antiviral interventions are only effective prior to the onset of hyperinflammation. Hence, biomarkers are needed for the early identification and treatment of high-risk patients. Here, we show in a range of model systems and data from post mortem samples that SARS-CoV-2 infection results in increased levels of CD47, which is known to mediate immune escape in cancer and virus-infected cells. Systematic literature searches also indicated that known risk factors such as older age and diabetes are associated with increased CD47 levels. High CD47 levels contribute to vascular disease, vasoconstriction, and hypertension, conditions which may predispose SARS-CoV-2-infected individuals to COVID-19-related complications such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury. Hence, CD47 is a candidate biomarker for severe COVID-19. Further research will have to show whether CD47 is a reliable diagnostic marker for the early identification of COVID-19 patients requiring antiviral therapy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing coronavirus disease 2019 outbreak [Hokello et al., 2020; Chilamakuri & Agarwal, 2021] , which has resulted in more than 100 million confirmed cases and more that 2 million confirmed COVID-19-associated deaths so far [Dong et al., 2020] .

The first COVID-19 vaccines have been developed [Chilamakuri & Agarwal, 2021] , and their roll-out has started in many countries. However, it will take a significant time until large parts of the world population will be vaccinated, and there is growing concern about the emergence of escape variants that can bypass immunity conferred by the current vaccines and previous SARS-CoV-2 infections [Andreano et al., 2020; Kemp et al., 2020; Liu et al., 2020; Weisblum et al., 2020; Sabino et al, 2021; Wibmer et al., 2021] . For the foreseeable future, there will thus be a need for improved COVID-19 therapies.

Currently, the therapeutic options for COVID-19 are still very limited [Chilamakuri & Agarwal, 2021; Rebold et al., 2021] . COVID-19 therapies can either directly inhibit SARS-CoV-2 replication or target other COVID-19-associated pathophysiological processes, such as corticosteroids that are anticipated to control COVID-19-related cytokine storm and hyperinflammation [Pum et al., 2021] .

Dexamethasone and potentially other corticosteroids increase survival in patients who depend on oxygen support [RECOVERY Collaborative Group, 2020; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, 2020] .

In a controlled open-label trial, dexamethasone reduced mortality in patients receiving oxygen with (from 41.1% to 29.3%) or without (from 26.2% to 23.3%) mechanical ventilation, but increased mortality in patients not requiring oxygen support [RECOVERY Collaborative Group, 2020] . Other immunomodulatory therapy candidates are being tested, but conclusive results are pending [Rebold et al., 2021] .

Further COVID-19 therapeutics under investigations include anticoagulants that target COVID-19-induced systemic coagulation and thrombosis (coagulopathy) [Hadid et al., 2020] .

However, it would be much better to have effective antiviral treatments that reliably prevent COVID-19 disease progression to a stage when immunomodulators and anticoagulants are needed. The antiviral drug remdesivir was initially described to reduce recovery time from 15 to ten days and 29-day mortality from 15.2% to 11.4% [Beigel et al., 2020; Rebold et al., 2021] . However, other trials did not confirm this and conclusive evidence on the efficacy of remdesivir remains to be established [Rebold et al., 2021] . The JAK inhibitor baricitinib, which interferes with cytokine signalling, was reported to improve therapy outcomes in combination with remdesivir in a double-blind, randomised, placebo-controlled trial, in which patients were either treated with remdesivir plus baricitinib or remdesivir plus placebo [Kalil et al., 2020] .

Moreover, convalescent sera and monoclonal antibodies are under clinical investigation for COVID-19 treatment [Tuccori et al., 2020; Devarasetti et al., 2021] .

Ideally, antiviral therapies are used early in the disease course to prevent disease progression to the later immunopathology-driven stages [Weinreich et al., 2021] . However, only a small proportion of patients develops severe disease [Salzberger et al., 2020] . Therefore, biomarkers are required that identify patients, who will develop severe disease, as early as possible.

Here, we investigated the potential of the ubiquitously expressed cell surface glycoprotein CD47 as biomarker for the identification of high-risk COVID-19 patients.

CD47 is the receptor of thrombospondin-1 (THBS1) and the counter-receptor for 6 signal regulatory protein-α (SIRPα). CD47 interaction with SIRPα inhibits the activation of macrophages and dendritic cells and thrombospondin-1/ CD47 signalling inhibits T cell activation [Cham et al., 2020; Kaur et al., 2020] . High CD47 expression prevents immune recognition of cancer and virus-infected cells [Cham et al., 2020; Kaur et al., 2020] . 7

Calu-3 cells (ATCC) were grown at 37°C in minimal essential medium (MEM) supplemented with 10% foetal bovine serum (FBS), 100 IU/mL penicillin, and 100 μ g/mL of streptomycin. All culture reagents were purchased from Sigma. Cells were regularly authenticated by short tandem repeat (STR) analysis and tested for mycoplasma contamination.

Primary human bronchial epithelial cells were purchased from ScienceCell. 

SARS-CoV-2/7/Human/2020/Frankfurt (SARS-CoV-2/FFM7) was isolated and cultivated in Caco2 cells (DSMZ) as previously described [Hoehl et al., 2020; Toptan et al., 2020] . Virus titres were determined as TCID50/ml in confluent cells in 96-well microtiter plates [Cinatl et al., 2003; Cinatl et al., 2005 ].

Confluent layers of CaCo-2 cells in 96-well plates were infected with SARS-CoV-2 FFM7 at a MOI of 0.01. Virus was added simultaneously with tested compound. 24 h post infection, cells were fixed with acetone:methanol (40:60) solution and immunostaining of spike protein was performed to determine infection rate. Briefly, a monoclonal antibody directed against the spike protein of SARS-CoV-2 (1:1,500, Sino Biological) was detected with a peroxidase-conjugated anti-rabbit secondary antibody (1:1,000, Dianova), followed by addition of AEC substrate. The spike positive area was scanned and quantified by automated plate reader. The results are expressed as percentage of infection relative to virus control which received no drug.

Cells were lysed using Triton-X-100 sample buffer, and proteins were separated by SDS-PAGE. Detection occurred by using specific antibodies against CD47 (1:100 dilution, CD47 Antibody, anti-human, Biotin, REAfinity™, # 130-101-343, Miltenyi Biotec), SARS-CoV-2 N (1:1000 dilution, SARS-CoV-2 Nucleocapsid Antibody, Rabbit MAb, #40143-R019, Sino Biological), and GAPDH (1:1000 dilution, Anti-G3PDH Human Polyclonal Antibody, #2275-PC-100, Trevigen). Protein bands were visualized and quantified by laser-induced fluorescence using infrared scanner for protein quantification (Odyssey, Li-Cor Biosciences). 

Normalized protein abundance data from SARS-CoV-2-infected Caco-2 cells were derived from a recent publication [Bojkova et al., 2020] . Data were subsequently normalised using summed intensity normalization for sample loading, followed by internal reference scaling and Trimmed mean of M normalization. Mean protein abundance was plotted using the function ggdotplot of the R package ggpubr. P-values were determined by two-sided student's t-test Raw read counts from post-mortem samples of two COVID-19 patients and two healthy controls, as well as mock infected and SARS-CoV-2-infected Calu-3 10 cells, were derived from a recent publication [Blanco-Melo et al., 2020] via the gene expression omnibus (GEO) database (accession: GSE147507) and processed using DESeq2. Normalised gene counts were plotted using the function ggdotplot of the R package ggpubr. P-values were determined by two-sided student's t-test

Relevant articles were identified by using the search terms 'CD47 aging', 'CD47 hypertension', 'CD47 diabetes', and 'CD47 obesity' in PubMed (https://pubmed.ncbi.nlm.nih.gov). Original articles in English were included into the analysis, when they contained on the influence of aging, diabetes, diabetes, or obesity on CD47 expression levels and/ or the relevance of CD47 with regard to pathological conditions observed in severe COVID-19.

A publicly available proteomics dataset [Bojkova et al., 2020] indicated increased in CD47 expression in SARS-CoV-2-infected Caco2 colorectal carcinoma cells ( Figure 1A) . We also detected enhanced CD47 levels in SARS-CoV-2-infected primary human bronchial epithelial cells (HBEpiC) grown in air liquid interface (ALI)

cultures [Bojkova et al., 2020A] and Calu-3 lung cancer cells ( Figure 1B) . Analysis of transcriptomics data from another study also indicated increased CD47 levels in SARS-CoV-2 -infected Calu-3 cells (Suppl. Figure 2) 

To further investigate a potential role of CD47 as biomarker indicating a high risk from COVID-19, we performed systematic literature searches on the relationship of CD47 and the known COVID-19 risk factors 'ageing', 'diabetes', and 'obesity'. (Suppl. Table 2 ). This resulted in 20 hits, including a further seven relevant studies ( Figure 2B , Suppl. Table 2 ).

Initial experiments showed that loss or inhibition of CD47 prevented age-and diet-induced vasculopathy and reduced damage caused by ischaemic injury in mice [Isenberg et al., 2007] . CD47-deficient mice indicated that CD47 functions as vasopressor and were also shown to be leaner and to display enhanced physical performance and a more efficient metabolism [Isenberg et al., 2009; Frazier et al., 2011] . In agreement, CD47 was upregulated in clinical pulmonary hypertension and contributed to pulmonary arterial vasculopathy and dysfunction in mouse models [Bauer et al., 2012; Rogers et al., 2017] . Age-related increased CD47 levels further affected peripheral blood flow and wound healing in mice and NO-mediated vasodilatation of coronary arterioles of rats [Nevitt et al., 2016] .

Moreover, thrombospondin-1/ CD47 signalling was shown to induce ageingassociated senescence in endothelial cells [Gao et al., 2016; Meijles et al., 2017] and age-associated deterioration in angiogenesis, blood flow, and glucose homeostasis [Ghimire et al., 2020] .

14 Increased CD47 levels were also detected in the lung of a sickle cell disease patient with pulmonary arterial hypertension, and vasculopathy and pulmonary hypertension were reduced in a CD47-null mouse model of sickle cell disease [Rogers et al., 2013a; Novelli et al., 2019] . Finally, anti-CD47 antibodies reversed fibrosis in various organs in mouse models [Wernig et al., 2017] , which may be relevant in the context of COVID-19-associated pulmonary fibrosis [Leeming et al., 2021] .

In addition to immunosuppressive activity, ageing-related increased CD47 levels may thus be involved in vascular disease, vasoconstriction, and hypertension and predispose COVID-19 patients to related pathologies such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury [Soto-Pantoja et al., 2013; Rogers et al., 2017a; Cruz Rodriguez et al., 2020; Fabrizi et al., 2020; Karmouty-Quintana et al., 2020; Scutelnic and Heldner, 2020; Leeming et al., 2021; Sanghvi et al., 2021; Shah et al., 2021] . 

Diabetes has been associated with an increased risk of severe COVID-19

and COVID-19-related death [Shah et al., 2021] . A PubMed search for "CD47 diabetes" produced 47 hits, nine of which reported on increased CD47 levels in response to hyperglycaemia and/ or diabetes (Figure 3 , Suppl. Table 3 ).

A "CD47 aging" n = 62

Full-text articles assessed n = 62

Full-text articles excluded n = 54

Include in qualitative synthesis n = 8 B THBS1 CD47

Cell membrane Age-related -vasoconstriction -hypertension -angiogenesis -ischaemic injury -senescence "CD47 hypertension" n = 20

Full-text articles assessed n = 20

Full-text articles excluded n = 13

Include in qualitative synthesis n = 7

COVID-19-related -pulmonary hypertension -lung fibrosis -myocardial injury -stroke -kidney injury C 16 Hyperglycaemia protected CD47 from cleavage resulting in increased CD47 levels [Maile et al., 2008; . In agreement, increased CD47 levels were detected in various cell types and tissues in rat diabetes models and diabetes patients [Abdul-Rahman et al., 2012; Abu El-Asrar et al., 2013; Wang et al., 2014; Bitar, 2019] . Therefore, diabetes-induced increased CD47 levels may interfere with the recognition of SARS-CoV-2-infected cells by the immune system [Cham et al., 2020; Kaur et al., 2020] . 

As obesity is another risk factor for severe COVID-19 [Shah et al., 2021] , we also performed a PubMed search for "CD47 obesity", which resulted in eight hits, two of which provided potentially relevant information (Suppl. Table 4 ). Results indicated that CD47-deficient mice were leaner, probably as a consequence of elevated lipolysis [Maimaitiyiming et al., 2015; Norman-Burgdolf et al., 2020] . Hence, low CD47 levels may be associated both with lower weight and increased immune recognition of virus-infected cells [Maimaitiyiming et al., 2015; Cham et al., 2020; Kaur et al., 2020; Norman-Burgdolf et al., 2020] , but there is no direct evidence suggesting that obesity may also directly increase CD47 expression. However, obesity may at least indirectly contribute to enhanced CD47 levels as risk factor for diabetes [Shah et al., 2021] .

Here, we show that SARS-CoV-2 infection is associated with increased CD47 expression in a range of model systems and in post mortem samples from COVID-19 patients. CD47 exerts immunosuppressive activity via interaction with SIRPα on immune cells and as thrombospondin-1 receptor [Cham et al., 2020; Kaur et al., 2020] . In this context, human CD47 expression is discussed as a strategy to enable the xenotransplantation of organs from pigs to humans [Cooper et al., 2019; Hosny et al., 2021] . Moreover, high CD47 expression is an immune escape mechanism observed on cancer cells, and anti-CD47 antibodies are under investigation as cancer immunotherapeutics [Feng et al., 2020; Kaur et al., 2020] . Due its immunosuppressive action, CD47 expression is also discussed as a target for the treatment of viral and bacterial pathogens including SARS-CoV-2 [Cham et al., Oronsky et al., 2020a; Tal et al., 2020] . Thus, our data indicating increased CD47 levels in a range of SARS-CoV-2 infection models and clinical samples further support the potential role of CD47 as drug target for the mediation of a more effective antiviral immune response.

Older age, diabetes, and obesity are known risk factors for COVID-19 morbidity and mortality [Hokello et al., 2020; Shah et al., 2021] . Hence, we performed a series of systematic reviews to identify potential connections between CD47 and these processes. Results indicated an ageing-related increase in CD47 expression, which may contribute the increased COVID-19 vulnerability in older patients [Hokello et al., 2020] . Moreover, high CD47 levels are known to be involved in vascular disease, vasoconstriction, and hypertension, which may predispose SARS-CoV-2-infected individuals to various conditions associated with severe COVID-19 related, including pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury [Soto-Pantoja et al., 2013; Rogers et al., 2017a; Cruz Rodriguez et al., 2020; Fabrizi et al., 2020; Karmouty-Quintana et al., 2020; Scutelnic and Heldner, 2020; Leeming et al., 2021; Sanghvi et al., 2021; Shah et al., 2021] .

High CD47 levels have also been reported as a consequence of hyperglycaemia and diabetes, which may contribute to the high risk of severe COVID-19 in diabetic patients [Shah et al., 2021] . Although there is no known direct impact of obesity on CD47 levels, obesity is associated with an increased risk of diabetes and other ageing-related conditions such as hypertension that may result in elevated COVID-19 vulnerability [Shah et al., 2021] .

Severe COVID-19 disease is the consequence of hyperinflammation ('cytokine storm') in response to SARS-CoV-2 infection [Jacques and Apedaile, 2020; Nowill and Campos-Lima, 2020; Gustine and Jones, 2021] . Hence, the optimal time window for antiviral intervention is as early as possible to prevent disease progression to severe stages driven by immunopathology [Weinreich et al., 2021] .

Since the vast majority of cases are mild or even asymptomatic [Salzberger et al., 2020] , biomarkers are required to identify and treat individuals early, who are at high risk of severe COVID-19.

Here, we have identified CD47 as a candidate biomarker for severe COVID-19. SARS-CoV-2 infection results in enhanced CD47 expression, which is known to interfere with the host immune response. Moreover, CD47 levels are elevated in groups at high risk from COVID-19 such as older individuals and individuals with hypertension and/ or diabetes. Thus, high CD47 levels may predispose these groups 20 to severe COVID-19. Further research will have to show whether CD47 is a reliable diagnostic marker for the early identification of COVID-19 patients requiring antiviral therapy.

Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats

Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy

Glucose-oxidized lowdensity lipoproteins enhance insulin-like growth factor I-stimulated smooth muscle cell proliferation by inhibiting integrin-associated protein cleavage

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv

Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res

Remdesivir for the Treatment of Covid-19 -Final Report

Diabetes Impairs Angiogenesis and Induces Endothelial Cell Senescence by Up-Regulating Thrombospondin-CD47-Dependent Signaling

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Aprotinin Inhibits SARS-CoV-2 Replication. Cells

COVID-19: Characteristics and Therapeutics

Glycyrrhizin, an active component of liquorice roots, and replication of SARSassociated coronavirus

High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells

Justification of specific genetic modifications in pigs for clinical organ xenotransplantation

Gamut of cardiac manifestations and complications of COVID-19: a contemporary review

A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy

An interactive web-based dashboard to track COVID-19 in real time

COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Pathogens

CD47: the next checkpoint target for cancer immunotherapy

Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47

Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells

CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis

Immunopathology of Hyperinflammation in COVID-19

Coagulation and anticoagulation in COVID-19

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan

A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19

3'UTR enhances hCD47 cell surface expression, self-signal function, and reduces ER stress in porcine fibroblasts

Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia

Thrombospondin-1: a physiological regulator of nitric oxide signaling

Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress

Immunopathogenesis of COVID-19: Summary and Possible Interventions. Front Immunol

ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets

Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment

Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv

Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo

Identification of compounds that inhibit IGF-I signaling in hyperglycemia

Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation

Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase nonreceptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes

CD47 deficiency protects mice from diet-induced obesity and improves whole body glucose tolerance and insulin sensitivity. Sci Rep

The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1

Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase

Physiological levels of thrombospondin-1 decrease NO-dependent vasodilation in coronary microvessels from aged rats

CD47 differentially regulates white and brown fat function

Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice

Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm

Just eat it: A review of CD47 and SIRP-α antagonism

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19

CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm

COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow

Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension

TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction

Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Epidemiology of SARS-CoV-2. Infection

Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis. Diagnostics (Basel)

Vascular Events, Vascular Disease and Vascular Risk Factors-Strongly Intertwined with COVID-19

The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19

Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets

Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. mBio

Optimized qRT-PCR Approach for the Detection of Intra-and Extra-Cellular SARS-CoV-2 RNAs

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins

MicroRNA miR-27b rescues bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus

Yancopoulos GD; Trial Investigators. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife

Unifying mechanism for different fibrotic diseases

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Metaanalysis

Nothing to declare.